We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+2.7%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$310M
AUM Growth
+$8.93M
Cap. Flow
+$4.99M
Cap. Flow %
1.61%
Top 10 Hldgs %
58.2%
Holding
58
New
5
Increased
12
Reduced
7
Closed
5

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$13.4M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$7.82M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$6.27M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$6.06M
5
XLRN
Acceleron Pharma
XLRN
+$5.28M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$20.1M
2
CCXI
ChemoCentryx, Inc.
CCXI
+$9.04M
3
ZGNX
Zogenix, Inc.
ZGNX
+$6.17M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$3.1M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$2.33M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$30.2M 9.76%
389,000
-45,000
-10% -$3.1M
NBIX icon
2
Neurocrine Biosciences
NBIX
$15.9B
$21.3M 6.89%
221,800
+116,000
+110% +$13.4M
GILD icon
3
Gilead Sciences
GILD
$185B
$20.3M 6.55%
321,284
+18,000
+6% +$1.25M
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$5.13B
$20M 6.47%
486,000
+181,000
+59% +$7.82M
BMRN icon
5
BioMarin Pharmaceuticals
BMRN
$12.6B
$18.8M 6.07%
247,584
+62,000
+33% +$6.27M
VRTX icon
6
Vertex Pharmaceuticals
VRTX
$139B
$17.6M 5.69%
64,822
– –
PTCT icon
7
PTC Therapeutics
PTCT
$5.99B
$14M 4.5%
299,000
– –
EXEL icon
8
Exelixis
EXEL
$13.7B
$12.9M 4.15%
526,534
+74,000
+16% +$1.73M
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
$12.8M 4.14%
65,500
+10,000
+18% +$1.67M
BIIB icon
10
Biogen
BIIB
$32.7B
$12.3M 3.99%
43,600
-7,600
-15% -$2.12M
AMGN icon
11
Amgen
AMGN
$236B
$11.2M 3.61%
44,000
-8,000
-15% -$1.98M
MYOK
12
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$8.98M 2.9%
65,859
– –
BHVN
13
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$8.93M 2.88%
137,400
+92,400
+205% +$6.06M
ALXN
14
DELISTED
Alexion Pharmaceuticals
ALXN
$8.6M 2.78%
75,241
-13,000
-15% -$1.4M
HALO icon
15
Halozyme
HALO
$12.1B
$8.07M 2.61%
307,633
– –
XLRN
16
DELISTED
Acceleron Pharma
XLRN
$7.98M 2.58%
71,000
+53,000
+294% +$5.28M
INCY icon
17
Incyte
INCY
$25.9B
$7M 2.26%
78,000
– –
REGN icon
18
Regeneron Pharmaceuticals
REGN
$83.1B
$6.43M 2.08%
11,500
– –
ALNY icon
19
Alnylam Pharmaceuticals
ALNY
$31.7B
$5.28M 1.7%
36,300
– –
IOVA icon
20
Iovance Biotherapeutics
IOVA
$3.75B
$4.77M 1.54%
+145,000
New +$4.45M
MRTX
21
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$4.46M 1.44%
26,900
-17,000
-39% -$2.33M
SRPT icon
22
Sarepta Therapeutics
SRPT
$2.29B
$4.42M 1.43%
31,500
+10,000
+47% +$1.52M
IMMU
23
DELISTED
Immunomedics Inc
IMMU
$4.22M 1.36%
49,700
-398,300
-89% -$20.1M
TPTX
24
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$3.05M 0.98%
35,000
– –
PTGX icon
25
Protagonist Therapeutics
PTGX
$9.68B
$2.97M 0.96%
+152,000
New +$2.85M
1
2 3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q3 2020 Portfolio in Review

As of Q3 2020, International Biotechnology Trust held 58 positions worth $310M, up 3% from $301M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

International Biotechnology Trust's Q3 2020 filing shows 5 new, 12 increased, 7 reduced and 5 closed positions. Its largest new stake was Iovance Biotherapeutics: 145,000 shares worth $4.77M. The largest sale was Immunomedics Inc, an estimated $20.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • International Biotechnology Trust's largest Q3 2020 buy was Iovance Biotherapeutics: 145,000 shares worth $4.77M.
  • International Biotechnology Trust added most to Neurocrine Biosciences in Q3 2020, an estimated $13.4M increase.
  • International Biotechnology Trust's biggest Q3 2020 reduction was Immunomedics Inc, cutting an estimated $20.1M.
  • International Biotechnology Trust fully exited Zogenix, Inc. in Q3 2020, selling an estimated $6.17M.
  • International Biotechnology Trust's ten largest holdings make up 58% of its $310M portfolio in Q3 2020.
  • International Biotechnology Trust opened 5 new positions and closed 5 in Q3 2020.
  • International Biotechnology Trust's portfolio value rose 3% quarter-over-quarter to $310M.

Based on International Biotechnology Trust's 13F filing for Q3 2020, filed 1 Dec 2020.